One study demonstrated that delivering DNA-damaging drugs to the cell nucleus could activate hnRNPA2B1, which, through a downstream cGAS-dependent pathway, promotes the production of IFN-β, mediating an anti-tumor effect. This evidence concerns the gene HNRNPA2B1 and neoplasm.